OR WAIT null SECS
Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.
, a company focused on the development of adoptive immunotherapies based on engineered allogeneic Universal Chimeric Antigen Receptor T-cells (UCART) and CELLforCURE, a subsidiary of the biopharmaceutical group LFB, have entered into an agreement in which CELLforCURE will be responsible for the cGMP manufacturing of clinical batches of Cellectis’ allogeneic CART cells. CELLforCURE operates a commercial industrial facility for the production of new therapeutic cell therapies in Les Ulis, France.
The candidates from the UCART product family are allogeneic cell therapy products based on the CAR (Chimeric Antigen Receptor) technology combined with genome engineering. According to the company, engineered allogeneic T-lymphocytes bearing a CAR directed at a tumor antigen are a new potential treatment for the various forms of leukemias, lymphomas, and solid tumors. UCARTs are “off-the-shelf” allogeneic products, which means that UCART production can be standardized, with consistent pharmaceutical release criteria, over time and from batch to batch. The favorable cost of such industrially manufactured treatments may help make them available to a broad patient population and avoid risks associated with the processing and the timing required for an autologous CART process.